Untreated AMD worsens vision

Article

Delaying treatment in patients with subfoveal neovascular age-related macular degeneration (wet AMD) correlates to progressive and substantial loss of visual acuity (VA), according to a report published online ahead of print by Eye.

Delaying treatment in patients with subfoveal neovascular age-related macular degeneration (wet AMD) correlates to progressive and substantial loss of visual acuity (VA), according to a report published online ahead of print by Eye.

Luis Arias, MD of Bellvitge University Hospital, Barcelona, Spain and colleagues conducted a retrospective, multicentre, epidemiological study of patients referred to retina specialists following a diagnosis of wet AMD.

The researchers found that the median time period elapsing between diagnosis and the first treatment visit was 2.3 months, and the percentage of patients with a VA of 20/400 or worse doubled from diagnosis (12.4%) to initial treatment visit (24.7%). Length of time between diagnosis and treatment showed a high statistically significant correlation to VA degeneration.

The team concluded that substantial VA loss results from untreated wet AMD.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.